AVBP (ArriVent BioPharma) Debt-to-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Debt-to-Asset?

ArriVent BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.16 Mil. ArriVent BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.01 Mil. ArriVent BioPharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $274.94 Mil. ArriVent BioPharma's debt to asset for the quarter that ended in Dec. 2024 was 0.00.

ArriVent BioPharma Debt-to-Asset Historical Data

The historical data trend for ArriVent BioPharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Debt-to-Asset Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

ArriVent BioPharma Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of ArriVent BioPharma's Debt-to-Asset

For the Biotechnology subindustry, ArriVent BioPharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArriVent BioPharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

ArriVent BioPharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

ArriVent BioPharma's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.162	+	0.014)	/	274.942
	=	0.00

ArriVent BioPharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.162	+	0.014)	/	274.942
	=	0.00

ArriVent BioPharma (NAS:AVBP) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

ArriVent BioPharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

ArriVent BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073

Website

https://www.arrivent.com

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.